Phillips Van-Heusen Q2
This article was originally published in The Rose Sheet
Executive Summary
Firm records $552.4 mil. in revenue for the second quarter, a 20% increase versus the comparable period a year ago, driven by a 27% increase in the firm's Calvin Klein licensing business, in particular its fragrance business with strong performance from CKIN2U fragrance and increased sales of men's and women's Euphoria fragrance, both of which are licensed, marketed and distributed by Coty. "The global demand for the Calvin Klein brand continues to expand as we introduce new product categories and enter into new markets around the world," Chairman and CEO Emanuel Chirico said...
You may also be interested in...
GE HealthCare Launches AI-Powered Voluson Ultrasound For Women’s Health
Voluson Signature 20 and 18 ultrasound provides clinicians with workflow efficiencies in detecting female reproductive health problems, especially those related to pregnancy.
CDER, CBER Not Seeing Hiring Slowdown Despite US FDA Warnings
FDA officials have said hiring could be slowed if an inflationary pay increase is not included in the agency budget, but CDER and CBER continue to add staff at a steady pace.
Medicare Reimbursement For Part B Drugs Is 48% Above 340B Prices To Hospitals, MedPAC Finds
New study updates past commission analyses and highlights the significant margin between Medicare payments for drugs and the prices paid by 340B-eligible providers.